These are top 10 stocks traded on the Robinhood UK platform in July
On Friday, Lucid (NASDAQ:LCID) Capital Markets initiated coverage on atai Life Sciences N.V (NASDAQ: ATAI), assigning a Buy rating to the stock. The firm set a price target of $12.00, highlighting the company’s extensive drug portfolio and its focus on revolutionizing mental health treatment. The stock, which has surged nearly 60% over the past six months and currently trades near its 52-week high of $2.64, has caught analysts’ attention with targets ranging from $5 to $11.
Lucid Capital Markets analysts pointed to atai’s rapid assembly of one of the largest drug portfolios in the psychedelic sector over the past seven years. The company, with a market capitalization of $495 million, is involved in four psychedelic programs aimed at addressing mental health issues, which affect a significant portion of the adult population in the United States. InvestingPro data shows the company maintains a strong financial position with more cash than debt and liquid assets exceeding short-term obligations.
The analysts noted that psychedelic drugs have been researched for over 75 years as potential treatments for mental illness. According to the National Institutes of Health, 23% of U.S. adults experience mental health conditions such as depression.
Atai is actively participating in more than 30 clinical programs targeting conditions like depression, anxiety, PTSD, and substance use disorder. The company was the first for-profit entity to invest in the psychedelic space, notably through its investment in COMPASS Pathways, which is leading pivotal testing for a depression treatment.
The coverage initiation by Lucid Capital Markets reflects a growing interest in the potential of psychedelic drugs to address widespread mental health challenges, positioning atai Life Sciences as a significant player in this emerging field. InvestingPro subscribers have access to 12 additional investment tips and comprehensive financial metrics to better evaluate atai’s growth potential in this emerging sector.
In other recent news, atai Life Sciences has reported positive topline data from a Phase 2a study of BPL-003 for treatment-resistant depression (TRD). The study revealed that a single dose of BPL-003, used alongside SSRIs, was well-tolerated and showed rapid, lasting antidepressant effects for up to three months. This aligns with earlier findings and supports further trials, with Phase 2b results expected by mid-2025. Additionally, atai Life Sciences announced a strategic merger with Beckley Psytech, forming a combined entity named atai Beckley. The merger, expected to complete in the second half of 2025, aims to create a leader in psychedelic mental health therapies, with Beckley shareholders receiving approximately 31% of the new company. The merger has received necessary board approvals and awaits shareholder approval. Furthermore, atai has initiated a Phase 2 trial for EMP-01, a potential treatment for social anxiety disorder, with topline data anticipated in early 2026. H.C. Wainwright maintains a Buy rating on atai, reflecting confidence in the company’s strategic developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.